Everolimus: side effect profile and management of toxicities in breast cancer (Q38125944)

29 August 2017

Everolimus: side effect profile and management of toxicities in breast cancer (English)

1 reference

29 August 2017

1 reference

3

Ruth O'Regan

1 reference

29 August 2017

Elisavet Paplomata

1

1 reference

29 August 2017

Amelia Zelnak

series ordinal

2

1 reference

29 August 2017

language of work or name

English

0 references

publication date

2 August 2013

1 reference

Breast Cancer Research and Treatment

29 August 2017

1 reference

29 August 2017

140

1 reference

29 August 2017

3

1 reference

29 August 2017

453-462

1 reference

https://scigraph.springernature.com/pub.10.1007/s10549-013-2630-y

29 August 2017

0 references

cites work

Cancer statistics, 2013

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2630-Y

Cancer treatment and survivorship statistics, 2012

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2630-Y

Targeting mTOR signaling for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2630-Y

Targeting the phosphoinositide-3 (PI3) kinase pathway in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2630-Y

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2630-Y

Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2630-Y

Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2630-Y

Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2630-Y

Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2630-Y

Clinical pharmacokinetics of everolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2630-Y

Everolimus: targeted therapy on the horizon for the treatment of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2630-Y

The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: results of a phase I study with pharmacokinetics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2630-Y

A phase 1 study of weekly everolimus (RAD001) in combination with docetaxel in patients with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2630-Y

Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2630-Y

Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2630-Y

Oral adverse events associated with tyrosine kinase and mammalian target of rapamycin inhibitors in renal cell carcinoma: a structured literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2630-Y

Clinical presentation and management of mTOR inhibitor-associated stomatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2630-Y

A review of oral toxicity associated with mTOR inhibitor therapy in cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2630-Y

Management of adverse events in patients with hormone receptor-positive breast cancer treated with everolimus: observations from a phase III clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2630-Y

Natural history, management and pharmacokinetics of everolimus-induced-oral ulcers: insights into compliance issues.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2630-Y

Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2630-Y

Rash to the mTOR inhibitor everolimus: systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2630-Y

Common toxicities of mammalian target of rapamycin inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2630-Y

mTOR inhibitor-associated dermatologic and mucosal problems

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2630-Y

Insulin-stimulated phosphorylation of lipin mediated by the mammalian target of rapamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2630-Y

A contemporary update on rates and management of toxicities of targeted therapies for metastatic renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2630-Y

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2630-Y

Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2630-Y

Management of treatment-related toxicity with targeted therapies for renal cell carcinoma: evidence-based practice and best practices

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2630-Y

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2630-Y

Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2630-Y

Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2630-Y

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2630-Y

Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2630-Y

Sirolimus-associated pulmonary toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2630-Y

Pneumonitis associated with mTOR inhibitors therapy in patients with metastatic renal cell carcinoma: incidence, radiographic findings and correlation with clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2630-Y

Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2630-Y

10.1007/S10549-013-2630-Y

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

29 August 2017

0 references

1 reference